OMER

Omeros Corp

9.91

Jun 29 • 04:00PM ET +1.24 (14.30%)

Healthcare Biotechnology USA Small NASD

Peers: KYMR NUVL RYTM INCY BMRN VKTX KRYS AXSM MDGL NBIX

| Held by: VTI IWM VXF XPH PBE VTWO IWN SCHA VFMO VHT

Scroll to Statements

Index	RUT
Market Cap	717.24M
Enterprise Value	892.55M
Income	86.17M
Sales	9.89M
Book/sh	-0.88
Cash/sh	1.87
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	175
IPO	Oct 08, 2009

P/E	11.58
Forward P/E	-
PEG	-
P/S	72.52
P/B	-
P/C	5.30
P/FCF	-
EV/EBITDA	-
EV/Sales	90.25
Quick Ratio	3.03
Current Ratio	3.03
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	0.86
EPS next Y	-0.28
EPS next Q	-0.25
EPS this Y	198.00%
EPS next Y	-674.08%
EPS next 5Y	-
EPS past 3/5Y	- 53.45%
Sales past 3/5Y	- -
EPS Y/Y TTM	141.64%
Sales Y/Y TTM	-
EPS Q/Q	235.26%
Sales Q/Q	-
Earnings	May 13 AMC
EPS/Sales Surpr.	260.75% 137.21%

Insider Own	3.56%
Insider Trans	-2.55%
Inst Own	43.90%
Inst Trans	-4.08%
ROA	32.23%
ROE	-
ROIC	38.99%
Gross Margin	84.83%
Oper. Margin	-1063.86%
Profit Margin	871.02%
SMA20	-0.67%
SMA50	-17.48%
SMA200	-3.64%
Trades

Shs Outstand	72.00M
Shs Float	69.80M
Short Float	25.94%
Short Ratio	10.09
Short Interest	18.10M
52W High	17.65 -43.85%
52W Low	2.95 235.93%
Volatility	9.69% 8.97%
ATR (14)	0.96
RSI (14)	45.00
Beta	2.55
Rel Volume	1.55
Avg Volume	1.79M
Volume	2,743,349

Perf Week	-4.07%
Perf Month	-11.12%
Perf Quarter	0.30%
Perf Half Y	-35.48%
Perf YTD	-42.30%
Perf Year	209.69%
Perf 3Y	86.63%
Perf 5Y	-34.24%
Perf 10Y	-6.07%
Recom	2.00
Target Price	44.00
Prev Close	8.67
Price	9.91
Change	14.30%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-10-25	Initiated	H.C. Wainwright	Buy	$9
Dec-23-24	Initiated	D. Boral Capital	Buy	$36
Nov-14-24	Initiated	Rodman & Renshaw	Buy	$9
Dec-08-22	Downgrade	UBS	Buy → Neutral	$12 → $2
Nov-08-22	Downgrade	BofA Securities	Neutral → Underperform	$8 → $3
Jun-08-22	Downgrade	BofA Securities	Buy → Neutral	$12 → $4
Oct-08-21	Downgrade	JP Morgan	Neutral → Underweight
Oct-01-21	Downgrade	Wedbush	Neutral → Underperform
Oct-01-21	Downgrade	Maxim Group	Buy → Hold
Sep-27-21	Initiated	JP Morgan	Neutral	$15
Feb-01-21	Initiated	UBS	Buy	$25
Oct-20-20	Initiated	BofA Securities	Buy	$21
Aug-21-20	Reiterated	H.C. Wainwright	Buy	$34 → $32
Aug-14-20	Reiterated	Maxim Group	Buy	$25 → $20
May-06-19	Initiated	Cantor Fitzgerald	Overweight	$26
Jul-12-18	Initiated	Seaport Global Securities	Buy	$30
Mar-23-18	Downgrade	Wedbush	Outperform → Neutral	$47 → $19
Mar-05-18	Downgrade	Needham	Buy → Hold
Nov-08-17	Initiated	H.C. Wainwright	Buy	$30
May-11-17	Downgrade	Cantor Fitzgerald	Buy → Neutral	$21 → $15

Show Previous Ratings

Jun-26-26 08:33AM	Why Is OMER Stock Falling Today? (Stocktwits) -19.12%
08:30AM	Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA (Business Wire)
Jun-15-26 08:30AM	Omeros Announces Webcast Details for Annual Meeting of Shareholders (Business Wire) +6.81%
May-14-26 08:30AM	Omeros Corporation Q1 2026 Earnings Call Summary (Moby) -7.65%
01:02AM	Omeros Corp (OMER) Q1 2026 Earnings Call Highlights: Strong YARTEMLEA Launch and Strategic ... (GuruFocus.com)
04:17PM	Loading…
May-13-26 04:17PM	Omeros: Q1 Earnings Snapshot (Associated Press)
04:02PM	Omeros Corporation Reports First Quarter 2026 Financial Results (Business Wire)
May-11-26 04:02PM	Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026 (Business Wire)
Apr-16-26 08:45AM	CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA (narsoplimab-wuug) (Business Wire)
Apr-10-26 08:11PM	Does Omeros (OMER) Have the Potential to Rally 266.67% as Wall Street Analysts Expect? (Quartz)
Apr-01-26 08:30AM	Omeros Corporation Q4 2025 Earnings Call Summary (Moby) +14.39%
Mar-31-26 11:02PM	Omeros Corp (OMER) Q4 2025 Earnings Call Highlights: A Turnaround with Strategic Deals and FDA ... (GuruFocus.com) +7.65%
04:22PM	Omeros: Q4 Earnings Snapshot (Associated Press)
04:02PM	Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results (Business Wire)
Mar-26-26 08:45AM	Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026 (Business Wire)
03:23AM	Loading…
Mar-21-26 03:23AM	Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment (Business Wire)
Feb-17-26 08:45AM	Omeros Announces Successful Primate Study in OncotoX-AML Drug Program (Business Wire)
Jan-27-26 09:00AM	Omeros Announces First Commercial Sales of YARTEMLEA (Business Wire) +9.89%
Dec-29-25 10:57AM	Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMA (Zacks) +5.47%
Dec-26-25 06:36PM	Omeros Announces New Date for YARTEMLEA Approval Conference Call (Business Wire)
Dec-24-25 05:42PM	Why Omeros Stock Skyrocketed Today (Motley Fool) +75.54%
09:00AM	FDA Approves Omeros' YARTEMLEA - First and Only Therapy Indicated for TA-TMA (Business Wire)
Dec-10-25 02:15PM	Omeros Corporation (OMER): Novo Nordisk Deal Creating Buzz (Insider Monkey)
Dec-08-25 08:24AM	Do You Believe Omeros Corporation's (OMER) New Monoclonal Antibody Has Strong Chances of Approval? (Insider Monkey) +5.07%
Dec-01-25 08:30AM	Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906) (Business Wire)
Nov-14-25 12:02AM	Omeros Corp (OMER) Q3 2025 Earnings Call Highlights: Strategic Moves and Financial Challenges (GuruFocus.com) +25.32%
Nov-13-25 05:33PM	Omeros: Q3 Earnings Snapshot (Associated Press Finance) -8.85%
04:11PM	Omeros Corporation Reports Third Quarter 2025 Financial Results (Business Wire)
Nov-11-25 08:30AM	Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025 (Business Wire)
Oct-26-25 06:05AM	Is Omeros Corporation (OMER) One of the Hot Stocks to Buy with Huge Upside Potential? (Insider Monkey)
08:16AM	Loading…
Oct-23-25 08:16AM	Breakout Momentum Plays You Need to Know About (MarketBeat)
Oct-22-25 07:41AM	Omeros Sells Exclusive Global Rights for Drug Zaltenibart to Novo Nordisk (Insider Monkey)
Oct-16-25 12:16PM	Novo Nordisk snaps up Omeros rare disease asset for up to $2.1bn (Pharmaceutical Technology) -5.66%
11:10AM	NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio (Zacks)
08:30AM	Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group (Business Wire)
03:39AM	A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now? (Motley Fool)
Oct-15-25 04:12PM	Omeros Catapults 154% On A Surprise $2.1 Billion Deal With Novo Nordisk (Investor's Business Daily) +154.15%
03:58PM	Novo Nordisk Just Signed a Key Drug Deal With Omeros. Is There Any Room Left for OMER Stock to Run? (Barchart)
12:49PM	Omeros Catapults Almost 150% On A Surprise $2.1 Billion Deal With Novo Nordisk (Investor's Business Daily)
11:25AM	Novo Nordisk to Buy Blood Disease Drug From Omeros for Up to $2.1 Billion (The Wall Street Journal)
10:52AM	Novo wagers up to $2.1B on Omeros rare disease drug (BioPharma Dive)
09:17AM	Novo Nordisk to Pay Omeros Up to $2.1 Billion For Blood Disease Drug (The Wall Street Journal)
Sep-02-25 08:45AM	Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program (Business Wire)
Aug-15-25 03:24AM	Omeros Corp (OMER) Q1 2025 Earnings Call Highlights: Strategic Debt Reduction and Narsoplimab ... (GuruFocus.com) +7.04%
Aug-14-25 04:08PM	Omeros: Q2 Earnings Snapshot (Associated Press Finance)
04:02PM	Omeros Corporation Reports Second Quarter 2025 Financial Results (Business Wire)
Aug-11-25 04:02PM	Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025 (Business Wire)
Jul-25-25 08:00AM	Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering (Business Wire) +6.69%
Jun-27-25 08:30AM	Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA (Business Wire)
Jun-24-25 08:30AM	Omeros Announces Webcast Details for Annual Meeting of Shareholders (Business Wire) +5.96%
Jun-03-25 09:35AM	Down 54.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Omeros (OMER) (Zacks)
May-16-25 08:13AM	Q1 2025 Omeros Corp Earnings Call (Thomson Reuters StreetEvents) -18.61%
03:13AM	Omeros Corp (OMER) Q1 2025 Earnings Call Highlights: Strategic Debt Reduction and Narsoplimab ... (GuruFocus.com)
May-15-25 04:34PM	Omeros: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Omeros Corporation Reports First Quarter 2025 Financial Results (Business Wire)
May-12-25 05:05PM	Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025 (Business Wire) -38.59% +16.73%
08:41AM	Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026 (Business Wire)
May-06-25 09:16AM	FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date (Business Wire) -6.90%
Apr-10-25 09:10AM	Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros Proprietary OncotoX-AML Clinical Program (Business Wire) -9.85%
Apr-08-25 09:00AM	Omeros Corporation To Introduce Its Proprietary T-CAT Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases (Business Wire) -12.55%
Apr-01-25 09:27AM	Q4 2024 Omeros Corp Earnings Call (Thomson Reuters StreetEvents)
03:03AM	Omeros Corp (OMER) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges with ... (GuruFocus.com)
Mar-31-25 08:57PM	Omeros Corporation (OMER) Q4 2024 Earnings Call Transcript (Seeking Alpha)
04:17PM	Omeros: Q4 Earnings Snapshot (Associated Press Finance)
04:02PM	Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results (Business Wire)
Mar-26-25 09:15AM	Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025 (Business Wire) -6.99%
Mar-24-25 07:58AM	Omeros to activate site for Phase III programme of zaltenibart for PNH (Clinical Trials Arena)
Mar-21-25 09:15AM	Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program (Business Wire)
Mar-13-25 09:00AM	Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Companys OMS527 Program to Treat Cocaine Use Disorder (Business Wire)
Feb-21-25 09:21AM	Omeros announces results for narsoplimab expanded access program (TipRanks)
Feb-20-25 09:10AM	Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA (Business Wire)
Feb-14-25 09:00AM	Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings (Business Wire)
Feb-10-25 09:00AM	Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program (Business Wire)
Jan-16-25 09:15AM	Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint (Business Wire)
Dec-19-24 10:46AM	Omeros Reports Narsoplimab TA-TMA Trial Success; Stock Surges (GuruFocus.com) +37.27%
09:15AM	Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint - Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA (Business Wire)
Dec-10-24 12:22PM	Omeros Corp (OMER): Profit-Taking Time Amid ASH Presentations and Financial Challenges (Insider Monkey) -7.38%
08:45AM	Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting (Business Wire)
Dec-02-24 08:45AM	Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting (Business Wire) +5.29%
Nov-22-24 02:31PM	Omeros Updates Progress on Narsoplimab Biologics License Resubmission; Stock up Over 30% on News (GuruFocus.com) +41.14%
Nov-21-24 09:15AM	Omeros Corporation Provides Update on Progress Toward BLA Resubmission (Business Wire) +28.19%
Nov-14-24 02:01PM	Q3 2024 Omeros Corp Earnings Call (Thomson Reuters StreetEvents) +65.87%
02:15AM	Omeros Corp (OMER) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Adjustments (GuruFocus.com)
Nov-13-24 04:17PM	Omeros: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	Omeros Corporation Reports Third Quarter 2024 Financial Results (Business Wire)
Nov-11-24 04:11PM	Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024 (Business Wire)
Oct-24-24 08:45AM	FDA Grants Rare Pediatric Disease Designation to Omeros MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy (Business Wire)
Aug-07-24 05:16PM	Omeros: Q2 Earnings Snapshot (Associated Press Finance) -5.03% -5.78%
04:02PM	Omeros Corporation Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-05-24 04:02PM	Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024 (Business Wire) -10.68%
Jun-04-24 09:00AM	Omeros Announces Webcast Details for Annual Meeting of Shareholders (Business Wire) -6.16%
Jun-03-24 09:00AM	Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028 (Business Wire) +20.83%
May-16-24 01:10PM	Q1 2024 Omeros Corp Earnings Call (Thomson Reuters StreetEvents) -20.62%
03:10AM	Omeros Corp (OMER) Q1 2024 Earnings Call Transcript Highlights: Financial Shifts and Strategic ... (GuruFocus.com)
May-15-24 08:55PM	OMER Stock Earnings: Omeros Misses EPS for Q1 2024 (InvestorPlace)
04:11PM	Omeros: Q1 Earnings Snapshot (Associated Press Finance)
04:02PM	Omeros Corporation Reports First Quarter 2024 Financial Results (Business Wire)
May-10-24 08:50AM	Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024 (Business Wire)
May-09-24 08:50AM	Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress (Business Wire)
Apr-02-24 12:41PM	Q4 2023 Omeros Corp Earnings Call (Thomson Reuters StreetEvents)

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Co-FounderDr. Gregory A. Demopulos M.D.

VP of FinanceMr. David J. Borges

VPMr. Peter B. Cancelmo J.D.

Ph.D.Dr. Pamela Pierce Palmer M.D.

Ph.D.Dr. George A. Gaitanaris M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cable Thomas J.	Director	May 22 '26	Option Exercise	10.84	7,500	81,300	42,567	May 27 06:21 PM
Cable Thomas J.	Director	May 22 '26	Sale	11.61	7,500	87,039	35,067	May 27 06:21 PM
Thomas Cable	Director	May 22 '26	Proposed Sale	11.96	7,500	89,700		May 22 04:33 PM
Demopulos Gregory A MD	Chairman, CEO & President	Feb 18 '26	Option Exercise	10.27	400,000	4,108,000	1,826,986	Feb 20 09:40 PM
Borges David J.	VP, Finance & CAO	Jan 13 '26	Option Exercise	3.06	30,000	91,800	30,000	Jan 14 05:25 PM
Borges David J.	VP, Finance & CAO	Jan 12 '26	Sale	12.72	30,000	381,600	0	Jan 14 05:25 PM
Borges David J.	VP, Finance & CAO	Jan 13 '26	Sale	12.31	30,000	369,315	0	Jan 14 05:25 PM
DAVID J BORGES	Officer	Jan 13 '26	Proposed Sale	12.31	30,000	369,315		Jan 13 04:31 PM
DAVID J BORGES	Officer	Jan 12 '26	Proposed Sale	12.72	30,000	381,600		Jan 12 04:32 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

OMER

Omeros Corp

Upgrade your Finviz experience